Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 528

1.

Randomised controlled trial of the short-term effects of OROS-methylphenidate on ADHD symptoms and behavioural outcomes in young male prisoners with attention-deficit/hyperactivity disorder (CIAO-II).

Asherson P, Johansson L, Holland R, Fahy T, Forester A, Howitt S, Lawrie S, Strang J, Young S, Landau S, Thomson L.

Trials. 2019 Dec 2;20(1):663. doi: 10.1186/s13063-019-3705-9.

2.

Prescription of benzodiazepines, z-drugs, and gabapentinoids and mortality risk in people receiving opioid agonist treatment: Observational study based on the UK Clinical Practice Research Datalink and Office for National Statistics death records.

Macleod J, Steer C, Tilling K, Cornish R, Marsden J, Millar T, Strang J, Hickman M.

PLoS Med. 2019 Nov 26;16(11):e1002965. doi: 10.1371/journal.pmed.1002965. eCollection 2019 Nov.

3.

Untreated help seekers in addiction services: an opportunity to reach under-served groups in research.

Boniface S, Strang J.

Lancet Psychiatry. 2019 Sep 25. pii: S2215-0366(19)30300-1. doi: 10.1016/S2215-0366(19)30300-1. [Epub ahead of print] No abstract available.

PMID:
31563448
4.

Adaptive Behavior in Youth with Autism Spectrum Disorder: The Role of Flexibility.

Bertollo JR, Strang JF, Anthony LG, Kenworthy L, Wallace GL, Yerys BE.

J Autism Dev Disord. 2019 Sep 13. doi: 10.1007/s10803-019-04220-9. [Epub ahead of print]

PMID:
31520244
5.

A contingency management intervention to reduce cannabis use and time to relapse in early psychosis: the CIRCLE RCT.

Johnson S, Rains LS, Marwaha S, Strang J, Craig T, Weaver T, McCrone P, King M, Fowler D, Pilling S, Marston L, Omar RZ, Craig M, Spencer J, Hinton M.

Health Technol Assess. 2019 Aug;23(45):1-108. doi: 10.3310/hta23450.

6.

Medication Treatment of Opioid Use Disorder.

Bell J, Strang J.

Biol Psychiatry. 2020 Jan 1;87(1):82-88. doi: 10.1016/j.biopsych.2019.06.020. Epub 2019 Jul 2. Review.

PMID:
31420089
7.

Clinical and cost-effectiveness of contingency management for cannabis use in early psychosis: the CIRCLE randomised clinical trial.

Sheridan Rains L, Marston L, Hinton M, Marwaha S, Craig T, Fowler D, King M, Omar RZ, McCrone P, Spencer J, Taylor J, Colman S, Harder C, Gilbert E, Randhawa A, Labuschagne K, Jones C, Stefanidou T, Christoforou M, Craig M, Strang J, Weaver T, Johnson S.

BMC Med. 2019 Aug 15;17(1):161. doi: 10.1186/s12916-019-1395-5.

8.

Opioid users' willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder.

Tompkins CNE, Neale J, Strang J.

J Subst Abuse Treat. 2019 Sep;104:64-71. doi: 10.1016/j.jsat.2019.06.007. Epub 2019 Jun 9.

9.

Take-Home Naloxone for the Emergency Interim Management of Opioid Overdose: The Public Health Application of an Emergency Medicine.

Strang J, McDonald R, Campbell G, Degenhardt L, Nielsen S, Ritter A, Dale O.

Drugs. 2019 Sep;79(13):1395-1418. doi: 10.1007/s40265-019-01154-5. Review.

10.

Drug Policy and the Public Good: a summary of the second edition.

Babor TF, Caulkins J, Fischer B, Foxcroft D, Medina-Mora ME, Obot I, Rehm J, Reuter P, Room R, Rossow I, Strang J.

Addiction. 2019 Nov;114(11):1941-1950. doi: 10.1111/add.14734. Epub 2019 Aug 14.

PMID:
31294867
11.

Rising opioid-related deaths in England and Scotland must be recognised as a public health crisis.

Kimber J, Hickman M, Strang J, Thomas K, Hutchinson S.

Lancet Psychiatry. 2019 Aug;6(8):639-640. doi: 10.1016/S2215-0366(19)30209-3. Epub 2019 Jun 11. No abstract available.

PMID:
31201043
12.

Adolescent perspectives about their participation in alcohol intervention research in emergency care: A qualitative exploration using ethical principles as an analytical framework.

Lynch E, McGovern R, Elzerbi C, Breckons M, Deluca P, Drummond C, Alam MF, Boniface S, Coulton S, Gilvarry E, McArdle P, Patton R, Russell I, Strang J, Kaner E.

PLoS One. 2019 Jun 12;14(6):e0217855. doi: 10.1371/journal.pone.0217855. eCollection 2019.

13.

Clarification re naloxone administered to study subject versus other overdose victim in the N-ALIVE pilot randomized trial.

Parmar MKB, Strang J, Choo L, Meade AM, Bird SM.

Addiction. 2019 Jul;114(7):1325. doi: 10.1111/add.14284. No abstract available.

PMID:
31161681
14.

Depot buprenorphine injections for opioid use disorder: Patient information needs and preferences.

Neale J, Tompkins CNE, Strang J.

Drug Alcohol Rev. 2019 Jul;38(5):510-518. doi: 10.1111/dar.12939. Epub 2019 May 26.

15.

Should we worry that take-home naloxone availability may increase opioid use?

Tas B, Humphreys K, McDonald R, Strang J.

Addiction. 2019 Oct;114(10):1723-1725. doi: 10.1111/add.14637. Epub 2019 Jun 12. No abstract available.

PMID:
31013396
16.

Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder.

Frost M, Bailey GL, Lintzeris N, Strang J, Dunlop A, Nunes EV, Jansen JB, Frey LC, Weber B, Haber P, Oosman S, Kim S, Tiberg F.

Addiction. 2019 Aug;114(8):1416-1426. doi: 10.1111/add.14636. Epub 2019 Jun 3.

17.
18.

Factors influencing recruitment to a randomised placebo-controlled trial of oral naltrexone and extended release implant naltrexone: Qualitative study.

Tompkins CNE, Neale J, Marsden J, Strang J.

J Subst Abuse Treat. 2019 Apr;99:52-60. doi: 10.1016/j.jsat.2019.01.012. Epub 2019 Jan 16.

PMID:
30797394
19.

Take-home naloxone and the politics of care.

Farrugia A, Fraser S, Dwyer R, Fomiatti R, Neale J, Dietze P, Strang J.

Sociol Health Illn. 2019 Feb;41(2):427-443. doi: 10.1111/1467-9566.12848.

PMID:
30710415
20.

The impact of opiate substitution treatment on mortality risk in drug addicts: a natural experiment study.

Steer CD, Macleod J, Tilling K, Lim AG, Marsden J, Millar T, Strang J, Telfer M, Whitaker H, Vickerman P, Hickman M.

Southampton (UK): NIHR Journals Library; 2019 Jan.

21.

Extended-release naltrexone versus standard oral naltrexone versus placebo for opioid use disorder: the NEAT three-arm RCT.

Strang J, Kelleher M, Mayet S, Day E, Hellier J, Byford S, Murphy C, McLennan B, Shearer J, Ryan E, Marsden J.

Health Technol Assess. 2019 Jan;23(3):1-72. doi: 10.3310/hta23030.

22.

Challenges in delivering personalised support to people with multiple and complex needs: qualitative study.

Neale J, Parkman T, Strang J.

J Interprof Care. 2019 Nov-Dec;33(6):734-743. doi: 10.1080/13561820.2018.1553869. Epub 2018 Dec 10.

PMID:
30526196
23.

Change in alcohol and other drug use during five years of continuous opioid substitution treatment.

Eastwood B, Strang J, Marsden J.

Drug Alcohol Depend. 2019 Jan 1;194:438-446. doi: 10.1016/j.drugalcdep.2018.11.008. Epub 2018 Nov 26.

PMID:
30502545
24.

How competent are people who use opioids at responding to overdoses? Qualitative analyses of actions and decisions taken during overdose emergencies.

Neale J, Brown C, Campbell ANC, Jones JD, Metz VE, Strang J, Comer SD.

Addiction. 2019 Apr;114(4):708-718. doi: 10.1111/add.14510. Epub 2018 Dec 28.

PMID:
30476356
25.

Associations Between Medical History, Cognition, and Behavior in Youth With Down Syndrome: A Report From the Down Syndrome Cognition Project.

Rosser TC, Edgin JO, Capone GT, Hamilton DR, Allen EG, Dooley KJ, Anand P, Strang JF, Armour AC, Frank-Crawford MA, Channell MM, Pierpont EI, Feingold E, Maslen CL, Reeves RH, Sherman SL.

Am J Intellect Dev Disabil. 2018 Nov;123(6):514-528. doi: 10.1352/1944-7558-123.6.514.

PMID:
30421968
26.

Revisiting the Link: Evidence of the Rates of Autism in Studies of Gender Diverse Individuals.

Strang JF, Janssen A, Tishelman A, Leibowitz SF, Kenworthy L, McGuire JK, Edwards-Leeper L, Mazefsky CA, Rofey D, Bascom J, Caplan R, Gomez-Lobo V, Berg D, Zaks Z, Wallace GL, Wimms H, Pine-Twaddell E, Shumer D, Register-Brown K, Sadikova E, Anthony LG.

J Am Acad Child Adolesc Psychiatry. 2018 Nov;57(11):885-887. doi: 10.1016/j.jaac.2018.04.023.

PMID:
30392631
27.

"They Thought It Was an Obsession": Trajectories and Perspectives of Autistic Transgender and Gender-Diverse Adolescents.

Strang JF, Powers MD, Knauss M, Sibarium E, Leibowitz SF, Kenworthy L, Sadikova E, Wyss S, Willing L, Caplan R, Pervez N, Nowak J, Gohari D, Gomez-Lobo V, Call D, Anthony LG.

J Autism Dev Disord. 2018 Dec;48(12):4039-4055. doi: 10.1007/s10803-018-3723-6.

PMID:
30140984
28.

Patient views of opioid pharmacotherapy biodelivery systems: Qualitative study to assist treatment decision making.

Neale J, Tompkins CNE, McDonald R, Strang J.

Exp Clin Psychopharmacol. 2018 Dec;26(6):570-581. doi: 10.1037/pha0000217. Epub 2018 Jul 23.

PMID:
30035579
29.

Drugs policy will not change as long as UK government refuses to acknowledge the need for change.

Robertson R, McAuley A, Macleod J, Strang J, McCallum A.

BMJ. 2018 Jun 20;361:k2604. doi: 10.1136/bmj.k2604. No abstract available.

PMID:
29925647
30.

Positive reinforcement targeting abstinence in substance misuse (PRAISe): Study protocol for a Cluster RCT & process evaluation of contingency management.

Metrebian N, Weaver T, Pilling S, Hellier J, Byford S, Shearer J, Mitcheson L, Astbury M, Bijral P, Bogdan N, Bowden-Jones O, Day E, Dunn J, Finch E, Forshall S, Glasper A, Morse G, Akhtar S, Bajaria J, Bennett C, Bishop E, Charles V, Davey C, Desai R, Goodfellow C, Haque F, Little N, McKechnie H, Morris J, Mosler F, Mutz J, Pauli R, Poovendran D, Slater E, Strang J.

Contemp Clin Trials. 2018 Aug;71:124-132. doi: 10.1016/j.cct.2018.06.008. Epub 2018 Jun 13.

PMID:
29908336
31.

Implants and depot injections for treating opioid dependence: Qualitative study of people who use or have used heroin.

Neale J, Tompkins CNE, McDonald R, Strang J.

Drug Alcohol Depend. 2018 Aug 1;189:1-7. doi: 10.1016/j.drugalcdep.2018.03.057. Epub 2018 May 25.

32.

Continuous opioid substitution treatment over five years: Heroin use trajectories and outcomes.

Eastwood B, Strang J, Marsden J.

Drug Alcohol Depend. 2018 Jul 1;188:200-208. doi: 10.1016/j.drugalcdep.2018.03.052. Epub 2018 May 16.

PMID:
29778774
33.

Building on feminist achievements to enhance choice for women seeking treatment.

Neale J, Tompkins CNE, Marshall AD, Treloar C, Strang J.

Addiction. 2018 Jun;113(6):1001-1002. doi: 10.1111/add.14226. No abstract available.

PMID:
29732702
34.

Memory-focused cognitive therapy for cocaine use disorder: Rationale, design and protocol for an external pilot randomised controlled trial.

Marsden J, Goetz C, Meynen T, Mitcheson L, Stillwell G, Eastwood B, Strang J, Grey N.

Contemp Clin Trials Commun. 2017 Nov 2;8:264-273. doi: 10.1016/j.conctc.2017.10.009. eCollection 2017 Dec.

35.

The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom.

Hickman M, Steer C, Tilling K, Lim AG, Marsden J, Millar T, Strang J, Telfer M, Vickerman P, Macleod J.

Addiction. 2018 Aug;113(8):1461-1476. doi: 10.1111/add.14188. Epub 2018 Apr 19.

36.

Opportunistic screening for alcohol use problems in adolescents attending emergency departments: an evaluation of screening tools.

Coulton S, Alam MF, Boniface S, Deluca P, Donoghue K, Gilvarry E, Kaner E, Lynch E, Maconochie I, McArdle P, McGovern R, Newbury-Birch D, Patton R, Phillips CJ, Phillips T, Rose H, Russell I, Strang J, Drummond C.

J Public Health (Oxf). 2019 Mar 1;41(1):e53-e60. doi: 10.1093/pubmed/fdy049.

37.

Overlap of heritable influences between cannabis use disorder, frequency of use and opportunity to use cannabis: trivariate twin modelling and implications for genetic design.

Hines LA, Morley KI, Rijsdijk F, Strang J, Agrawal A, Nelson EC, Statham D, Martin NG, Lynskey MT.

Psychol Med. 2018 Dec;48(16):2786-2793. doi: 10.1017/S0033291718000478. Epub 2018 Mar 13.

PMID:
29530110
38.

Memory-Focused Cognitive Therapy for Cocaine Use Disorder: Theory, Procedures and Preliminary Evidence From an External Pilot Randomised Controlled Trial.

Marsden J, Goetz C, Meynen T, Mitcheson L, Stillwell G, Eastwood B, Strang J, Grey N.

EBioMedicine. 2018 Mar;29:177-189. doi: 10.1016/j.ebiom.2018.01.039. Epub 2018 Feb 2.

39.

Do women with complex alcohol and other drug use histories want women-only residential treatment?

Neale J, Tompkins CNE, Marshall AD, Treloar C, Strang J.

Addiction. 2018 Jun;113(6):989-997. doi: 10.1111/add.14131. Epub 2018 Jan 24.

40.

Improving recruitment to pharmacological trials for illicit opioid use: findings from a qualitative focus group study.

Neale J, Tompkins CNE, McDonald R, Strang J.

Addiction. 2018 Jun;113(6):1066-1076. doi: 10.1111/add.14163. Epub 2018 Feb 21.

41.

Development and early validation of a patient-reported outcome measure to assess sleep amongst people experiencing problems with alcohol or other drugs.

Neale J, Vitoratou S, Lennon P, Meadows R, Nettleton S, Panebianco D, Strang J, Marsden J.

Sleep. 2018 Apr 1;41(4). doi: 10.1093/sleep/zsy013.

42.

Substance use, sleep and intervention design: insights from qualitative data.

Neale J, Meadows R, Nettleton S, Panebianco D, Strang J, Vitoratou S, Marsden J.

J Ment Health. 2019 Oct;28(5):482-489. doi: 10.1080/09638237.2017.1417560. Epub 2017 Dec 21.

PMID:
29265898
43.

Value for money in reducing opioid-related deaths.

Hall W, Strang J.

Lancet Public Health. 2017 Mar;2(3):e124-e125. doi: 10.1016/S2468-2667(17)30027-0. Epub 2017 Feb 10. No abstract available.

44.

Norbuprenorphine and respiratory depression: Exploratory analyses with new lyophilized buprenorphine and sublingual buprenorphine
.

Strang J, Knight A, Baillie S, Reed K, Bogdanowicz K, Bell J.

Int J Clin Pharmacol Ther. 2018 Feb;56(2):81-85. doi: 10.5414/CP203118.

PMID:
29231163
45.

Preventing blood-borne virus infection in people who inject drugs in the UK: systematic review, stakeholder interviews, psychosocial intervention development and feasibility randomised controlled trial.

Gilchrist G, Swan D, Shaw A, Keding A, Towers S, Craine N, Munro A, Hughes E, Parrott S, Mdege N, Strang J, Taylor A, Watson J.

Health Technol Assess. 2017 Nov;21(72):1-312. doi: 10.3310/hta21720.

46.

Toxicity: exploring and expanding the concept.

Strang J, Neale J, McDonald R, Kalk N.

Addiction. 2018 Apr;113(4):592-594. doi: 10.1111/add.14080. Epub 2017 Dec 4. No abstract available.

PMID:
29205614
47.

Excess overdose mortality immediately following transfer of patients and their care as well as after cessation of opioid substitution therapy.

Bogdanowicz KM, Stewart R, Chang CK, Shetty H, Khondoker M, Day E, Hayes RD, Strang J.

Addiction. 2018 May;113(5):946-951. doi: 10.1111/add.14114. Epub 2018 Jan 10.

PMID:
29179255
48.

Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study.

McDonald R, Lorch U, Woodward J, Bosse B, Dooner H, Mundin G, Smith K, Strang J.

Addiction. 2018 Mar;113(3):484-493. doi: 10.1111/add.14033. Epub 2017 Nov 16.

49.

Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review.

Larney S, Peacock A, Leung J, Colledge S, Hickman M, Vickerman P, Grebely J, Dumchev KV, Griffiths P, Hines L, Cunningham EB, Mattick RP, Lynskey M, Marsden J, Strang J, Degenhardt L.

Lancet Glob Health. 2017 Dec;5(12):e1208-e1220. doi: 10.1016/S2214-109X(17)30373-X. Epub 2017 Oct 23. Review.

50.

Transgender Youth Fertility Attitudes Questionnaire: Measure Development in Nonautistic and Autistic Transgender Youth and Their Parents.

Strang JF, Jarin J, Call D, Clark B, Wallace GL, Anthony LG, Kenworthy L, Gomez-Lobo V.

J Adolesc Health. 2018 Feb;62(2):128-135. doi: 10.1016/j.jadohealth.2017.07.022. Epub 2017 Oct 20.

PMID:
29033160

Supplemental Content

Loading ...
Support Center